This feature article was created with the approval of the research team featured
Questions remain about how well it absorbs, how consistent the dosing is, and whether it produces effects as reliable as the injectable form
The Rise of GLP-1 Medications Parallel to telehealths expansion is the meteoric rise of GLP-1 receptor agonists, once primarily prescribed for diabetes, now a frontline treatment for obesity and weight management
Causes : Injecting near a vein, pressing too hard, or not rotating injection sites increases bruising risk
Recent Developments in May 2026 & Recent Industry Updates:- In May 2025, #BauschHealthandSalixPharmaceuticals announced new findings showing that #Xifaxan (rifaximin) treatment following #OvertHepaticEncephalopathy hospitalization was associated with a reduced risk of 30-day OHE-related rehospitalization
Other causes may include nerve compression, poor circulation, medical conditions, and deficiencies in key nutrients like magnesium or potassium
